These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 3744938

  • 1. In vivo modulation of glutathione by buthionine sulfoximine: effect on marrow response to melphalan.
    Russo A, Tochner Z, Phillips T, Carmichael J, DeGraff W, Friedman N, Fisher J, Mitchell JB.
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1187-9. PubMed ID: 3744938
    [Abstract] [Full Text] [Related]

  • 2. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy.
    Siemann DW, Beyers KL.
    Br J Cancer; 1993 Dec; 68(6):1071-9. PubMed ID: 8260357
    [Abstract] [Full Text] [Related]

  • 3. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.
    Ozols RF, Louie KG, Plowman J, Behrens BC, Fine RL, Dykes D, Hamilton TC.
    Biochem Pharmacol; 1987 Jan 01; 36(1):147-53. PubMed ID: 3801051
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice.
    Smith AC, Liao JT, Page JG, Wientjes MG, Grieshaber CK.
    Cancer Res; 1989 Oct 01; 49(19):5385-91. PubMed ID: 2766304
    [Abstract] [Full Text] [Related]

  • 5. Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow.
    Ono K, Shrieve DC.
    J Natl Cancer Inst; 1987 Oct 01; 79(4):811-5. PubMed ID: 3477662
    [Abstract] [Full Text] [Related]

  • 6. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
    Kramer RA, Greene K, Ahmad S, Vistica DT.
    Cancer Res; 1987 Mar 15; 47(6):1593-7. PubMed ID: 3815359
    [Abstract] [Full Text] [Related]

  • 7. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
    O'Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T, Brennan J, Bookman MA, Hoffman J, Young RC, Comis RL, Ozols RF.
    J Clin Oncol; 1996 Jan 15; 14(1):249-56. PubMed ID: 8558205
    [Abstract] [Full Text] [Related]

  • 8. Melphalan-induced toxicity in nude mice following pretreatment with buthionine sulfoximine.
    Skapek SX, VanDellen AF, McMahon DP, Postels DG, Griffith OW, Bigner DD, Friedman HS.
    Cancer Chemother Pharmacol; 1991 Jan 15; 28(1):15-21. PubMed ID: 2040029
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of the protective effect of cyclophosphamide by pre-treatment with buthionine sulfoximine.
    Carmichael J, Friedman N, Tochner Z, Adams DJ, Wolf CR, Mitchell JB, Russo A.
    Int J Radiat Oncol Biol Phys; 1986 Jul 15; 12(7):1191-3. PubMed ID: 3744939
    [Abstract] [Full Text] [Related]

  • 10. Combined effect of buthionine sulfoximine and cyclophosphamide upon murine tumours and bone marrow.
    Ono K, Komuro C, Tsutsui K, Shibamoto Y, Nishidai T, Takahashi M, Abe M, Shrieve DC.
    Br J Cancer; 1986 Nov 15; 54(5):749-54. PubMed ID: 3801271
    [Abstract] [Full Text] [Related]

  • 11. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.
    Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M, Spriggs DR.
    J Clin Oncol; 1994 Jan 15; 12(1):194-205. PubMed ID: 8270977
    [Abstract] [Full Text] [Related]

  • 12. Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice.
    Skapek SX, Colvin OM, Griffith OW, Elion GB, Bigner DD, Friedman HS.
    Cancer Res; 1988 May 15; 48(10):2764-7. PubMed ID: 3359437
    [Abstract] [Full Text] [Related]

  • 13. Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO.
    Gallo JM, Brennan J, Hamilton TC, Halbherr T, Laub PB, Ozols RF, O'Dwyer PJ.
    Cancer Res; 1995 Oct 15; 55(20):4507-11. PubMed ID: 7553617
    [Abstract] [Full Text] [Related]

  • 14. Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoximine-mediated glutathione depletion.
    Friedman HS, Colvin OM, Griffith OW, Lippitz B, Elion GB, Schold SC, Hilton J, Bigner DD.
    J Natl Cancer Inst; 1989 Apr 05; 81(7):524-7. PubMed ID: 2921776
    [Abstract] [Full Text] [Related]

  • 15. Depletion of tumour versus normal tissue glutathione by buthionine sulfoximine.
    Lee FY, Allalunis-Turner MJ, Siemann DW.
    Br J Cancer; 1987 Jul 05; 56(1):33-8. PubMed ID: 3620316
    [Abstract] [Full Text] [Related]

  • 16. Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan.
    Prezioso JA, FitzGerald GB, Wick MM.
    J Invest Dermatol; 1992 Sep 05; 99(3):289-93. PubMed ID: 1512464
    [Abstract] [Full Text] [Related]

  • 17. Cytotoxic effects of glutathione synthesis inhibition by L-buthionine-(SR)-sulfoximine on human and murine tumor cells.
    Dorr RT, Liddil JD, Soble MJ.
    Invest New Drugs; 1986 Sep 05; 4(4):305-13. PubMed ID: 3583642
    [Abstract] [Full Text] [Related]

  • 18. Effects of glutathione depletion by buthionine sulfoximine on radiosensitization by oxygen and misonidazole in vitro.
    Shrieve DC, Denekamp J, Minchinton AI.
    Radiat Res; 1985 Jun 05; 102(3):283-94. PubMed ID: 4070545
    [Abstract] [Full Text] [Related]

  • 19. Potentiation of the cytostatic effect of melphalan on colorectal cancer hepatic metastases by infusion of buthionine sulfoximine (BSO) in the rat: enhanced tumor glutathione depletion by infusion of BSO in the hepatic artery.
    Vahrmeijer AL, van Dierendonck JH, Schutrups J, van de Velde CJ, Mulder GJ.
    Cancer Chemother Pharmacol; 1999 Jun 05; 44(2):111-6. PubMed ID: 10412944
    [Abstract] [Full Text] [Related]

  • 20. Enhancement of EMT6/SF tumor cell killing by mitomycin C and cyclophosphamide following in vivo administration of buthionine sulfoximine.
    Ono K, Shrieve DC.
    Int J Radiat Oncol Biol Phys; 1986 Jul 05; 12(7):1175-8. PubMed ID: 3091546
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.